Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.
News|Articles|May 13, 2008
Pending drug-eluting stents are expected to lower prices in this market
A market research firm forecasts that more drug-eluting stents are on the way, which will bring down the costs of these devices.
Advertisement
Medtronic’s drug-eluting stent (DES),
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.
This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.
In part 2 of our discussion with Kimberly Kue-Tsemo, PharmD, she addresses the emergence of technology and the nuances behind its actual capabilities.
In part 2, Allison Schneider, MPH, discusses PBM and 340B reform that could compound pharmacies’ burden amid ongoing Medicare drug price negotiations.
Advertisement
Advertisement
Trending on Drug Topics
1
Updated Diabetes Consensus Shifts Focus from Glucose Control to Whole-Person Care
2
What the CLARITY Study Means for Counseling on Long-Acting HIV PrEP
3
Q&A: Overlapping PBM, 340B Reform Create Uncertainty for Pharmacies
4
No Added Adverse Event Risk in Pfizer-BioNTech COVID-19 Vaccine
5